Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function in SARSCoV2 Associated Acute Myocardial Injury With Heightened Inflammation

NCT04365153 is registered in ClinicalTrials.gov with The Cleveland Clinic as lead sponsor.

NCT NCT04365153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04365153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function in SARSCoV2 Associated Acute Myocardial Injury With Heightened Inflammation
Lead sponsor
The Cleveland Clinic
Phase
Phase 2
Overall status
Completed
Start date
April 24, 2020
Completion date
April 1, 2021
Enrollment
45 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov 2